Corrigendum to "Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG oncology study (NRG-GY008)" [Gynecol. Oncol. Rep. 31 (2020) 100532]
Gynecol Oncol Rep. 2020 May 28:33:100590.
doi: 10.1016/j.gore.2020.100590.
eCollection 2020 Aug.
1 Department of Obstetrics, Gynecology & Reproductive Services, Yale University School of Medicine, New Haven, CT 06520, USA.
2 NRG Oncology Statistical and Data Management Center, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
3 Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.
4 Medical Oncology, Women & Infants Hospital, 101 Dudley Street, Providence, RI 02905, USA.
5 Gynecologic Oncology, 980 Johnson Ferry Road #910, Atlanta, GA 30342, USA.
6 Department of Obstetrics & Gynecology, University of Oklahoma, The Stephenson Cancer Center, 800 NE 10th Street, Suite 2500, Oklahoma City, OK 73104, USA.
7 Gynecologic Oncology, University of New Mexico, 1201 Camino de Salud, Albuquerque, NM 87102, USA.
8 Department of Obstetrics & Gynecology, Northwestern Medicine Regional Medical Group, 4405 Weaver Parkway, Warrenville, IL 60555-3269, USA.
9 NRG Oncology, Operations Center-Philadelphia East, Philadelphia, PA, USA.
10 Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
11 Division of Hematology/Oncology, O'Neal Cancer Center University of Alabama, 176F 10390, 619 19th Street S, Birmingham, AL, USA.